CD24 as a Potential Therapeutic Target in Prostate Cancer
Annual rept. 7 Apr 2008-6 Mar 2009
MICHIGAN UNIV ANN ARBOR
Pagination or Media Count:
This is the first annual report on the grant CD24 as a Potential Therapeutic Target in Prostate Cancer. CD24 heat-stable antigen is a cell surface GPI-anchored mucin-like glycoprotein with broad expression on a variety of cell types, including hematopoietic cells, neuronal cells and various epithelial cells. There are accumulating evidence showing CD24 plays an important role in tumor development and tumor metastasis. We hypothesized that the expression of CD24 on both tumor cells and hematopoietic cells promotes tumor cell growth and metastasis. Therapeutic reagents target CD24 may block the tumor growth and metastasis. We proposed 1. To examine whether the intrinsic or extrinsic function of CD24 determine the prostate cancer incidence. 2. To examine whether CD24 expression affects the T cell priming and effector function to tumor antigen. 3 To examine whether CD24-IgG fusion protein can be used in immunotherapy of prostate cancer. The annual report summarized the results from specific aim 1 and 2.
- Medicine and Medical Research